Ulthera Receives Clearance to Market Ultrasound Platform Device in Brazil
Ulthera, Inc. -- a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology -- today announced that it is now registered in Brazil to market and distribute its patented medical device, the Ulthera System. The System -- which combines time-honored ultrasound imaging with focused ultrasound therapy in a treatment known as Ultherapy -- is cleared in the country to treat the face to encourage the natural formation of collagen and elastin in the skin, giving it the ability to lift tissue.
According to the International Society of Aesthetic Plastic Surgery (ISAPS), Brazil most recently ranked second in the world -- after the U.S. -- in both surgical and non-surgical procedures performed country-wide. "Bringing the Ulthera System into this already booming cosmetic market will greatly extend the global reach and popularity of non-invasive Ultherapy procedures," said Matthew Likens, president and CEO of Ulthera. "We anticipate -- and have already experienced -- high patient and physician demand for this efficacious treatment in Brazil, just as we have had in North America, Asia and Europe in our three years of commercialization to date."
MedSystems, an importer and distributor of clinical and aesthetic medical equipment and technology, will be the exclusive distributor of the Ulthera System in this important new market.
"Brazilian physicians have been anxiously awaiting Ulthera's arrival. After seeing how successful it has been in the U.S. -- and in nearly 40 other countries -- many of Brazil's aesthetic physician leaders were ready to bring the Ulthera System into their practices as soon as the ink was dry on the certification document," commented José Luiz Pinto, commercial director at MedSystems.
Pinto continued, "We view Ulthera as an esteemed and long-term partner. The promise this ultrasound platform technology holds is not only valuable to MedSystems as a distributor of the System, but also to our physician customers who can depend on Ulthera's continued innovation of the System that will bring them more value during each year of ownership."
"MedSystems brings a wealth of experience in the aesthetics market," mentioned Likens. "This, combined with its dedication to customer support and reputation for distributing superior technology, makes them the ideal partner to help accelerate the placement of Ulthera Systems in qualified physician practices across the country."
The Ulthera System is cleared by the U.S. FDA for use in a non-invasive treatment of the face to lift the eyebrow to achieve a desired aesthetic effect. More than 1,000 Ulthera Systems have been sold around the world and more than 100,000 treatments have been performed using it.
About UltheraUlthera®, Inc. is a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® -- the procedure enabled by the System -- is a non-invasive treatment of the face to achieve a brow lift. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company backed by top-tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ultherapy.com.
About MedSystemsFounded in 2002, MedSystems is an exclusive importer and distributor of equipment and technologies geared to meet doctors' needs who specialize in clinical and aesthetic procedures. The Company represents international brands whose strengths are reflected in high technology, superior quality, safety, clinical excellence and training aimed at providing full satisfaction to physicians and patients. For more information, visit www.medsystems.com.br.
Add to Digg Bookmark with del.icio.us Add to Newsvine